PEPTIDEPEDIA
Rejoindre
CJC-1295 + GHRP-6: Study-Material and Evidence Boundaries illustration
Mélange commercialisé
B 0062026-08-06

CJC-1295 + GHRP-6: Study-Material and Evidence Boundaries

Tous les mélangesCJC-1295 (no DAC)GHRP-6
Représentation de structure idéalisée pour CJC-1295 + GHRP-6: Study-Material and Evidence Boundaries
B 006CJC-1295 (no DAC) · GHRP-6

Conformère idéalisé construit à partir de la séquence ; il ne s’agit ni d’une structure expérimentale ni d’une structure prédite.

Le contenu des preuves est maintenu en anglais.

Bottom line

A marketed growth-hormone-axis combination pairing a substance labeled “CJC-1295 (no DAC)” with GHRP-6, a first-generation hexapeptide ghrelin-receptor agonist. Acute human component studies report GH release from GHRP-6, while a feeding response has been demonstrated directly in rats. No combination-specific study was identified.

No established or recommended human dose.

Name and formulation variability

| Market observation (source/date) | Claimed components and amounts | Verification limits | |---|---|---|---| | Online-market listings observed in 2026 | No-DAC identity caveat: substance labeled “CJC-1295 (no DAC)” plus GHRP-6; variable amount | Seller-declared identity and amount are not independent verification; “no DAC” means Modified GRF 1-29 rather than the DAC conjugate studied as CJC-1295 |

Also known as: CJC-1295/GHRP-6, Mod GRF 1-29/GHRP-6. GHRP-6 was first synthesised in 1984 as an enkephalin analog without opioid activity.

Critical ambiguity: the clinical-study name CJC-1295 refers to the DAC conjugate designed for albumin binding. Online-market “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a different substance. Evidence for CJC-1295 DAC cannot be transferred to Modified GRF 1-29 or this blend.

Study-material boundary
CJC-1295 DAC and separate GHRP-6 studies do not test the no-DAC marketed pairThree exact-identity nodes separate CJC-1295 with DAC, marketed CJC-1295 no DAC, and GHRP-6. Only the latter two have dotted market links, while study cards remain attached to their own identities.CJC-1295 WITH DACMARKETED CJC-1295NO DACGHRP-6WITH-DACstudy cardGHRP-6human endocrine studiesMARKETED PAIRDIFFERENT CJC IDENTITYSEPARATE-COMPONENT EXPOSURECOMBINATION EVIDENCE — NOT IDENTIFIEDIDENTITYHYPOTHESIZED / SHARED DOMAINMARKET ASSOCIATIONEVIDENCE GAP
Blocked arrows mark the different CJC identity and separate-component exposure. Legend: solid outlines identify the substances described on the page; dashed lines show hypothesized or shared biological domains; dotted lines show market association only; barred lines mark missing combination or compatibility evidence.
Alternative textuelle

CJC-1295 with DAC has a separate study record but is a different identity from the marketed no-DAC label. GHRP-6 has separate small human endocrine studies. Only the no-DAC label and GHRP-6 are market-associated with the pair, and no combination evidence was identified.

Component evidence

ComponentSeparate evidenceCombination evidenceCompatibility
CJC-1295 no DACDesign: no controlled human study of the exact material identified. Endpoint type: receptor activity inferred from sequence and class. Limitation: DAC evidence concerns a different identity.Shared gap: not identifiedNo published data
GHRP-6Design: small acute human endocrine studies. Endpoint type: GH and other pituitary-hormone responses, not therapeutic outcomes. Limitation: GHRP-6 alone or with GHRH is not this marketed pair.Shared gap: not identifiedNot identified

GHRP-6's appetite effect is commonly presented as a differentiator from more selective secretagogues. Direct evidence identified here is : an intracerebroventricular rat study reported increased feeding after GHRP-6. That animal observation does not establish a human appetite effect or the effect, safety, or value of this marketed combination.

A separate uncontrolled phase 1 report by Selman-Housein et al. enrolled 18 healthy adults aged 18–35 years, three at each of six single exposures from 1 to 400 mcg/kg. It recorded 23 adverse events in 12 participants and no serious adverse event. This small dose-escalation study did not test the blend.

Study detail

Ilson 1989 studied 17 healthy men during 30-minute IV infusions of 0.05–2.5 mcg/kg and included eight saline control infusions; GH increased with exposure and peaked at 45 minutes. Bowers 1990 studied 18 healthy men after IV boluses of 0.1, 0.3, or 1 mcg/kg, alone or with GHRH at 1 mcg/kg. GH responses were exposure-related, the two lower combined exposures were described as synergistic, and prolactin and cortisol rose about twofold only at the highest GHRP-6 exposure. A separate uncontrolled report enrolled 18 healthy adults across six single-exposure cohorts and did not test the blend. These descriptive records are not instructions.

Combination-specific studies

A targeted PubMed search through 2026-08-06 identified no published human or animal study testing CJC-1295 + GHRP-6 as a specific combination. Related GHRH-analog and GHRP-6 findings come from separate component literature.

Safety and interaction uncertainties

  • Appetite stimulation has direct support but was not established in the cited human studies

  • Cortisol/prolactin elevation at the highest acute GHRP-6 exposure complicates endocrine readouts

  • No combination-specific safety data

  • Fixed-ratio blend prevents independent dose adjustment of either component

Regulatory and product-quality notes

  • Neither component FDA-approved

  • The cited human GHRP-6 studies were acute or single-exposure studies and do not establish therapeutic efficacy

  • The 2026 List explicitly names CJC-1295 among GHRH analogues and GHRP-6 among GH-releasing peptides in section S2.2.4; both are prohibited at all times

  • An online “research use only” label is not authorization for human use

Evidence gaps

  • No combination study of any kind

  • No dose-ratio optimisation

  • No co-stability or co- characterisation

  • Long-term safety was not established in the cited individual-component studies or for the combination

Compare the identity boundary in CJC-1295 + Ipamorelin and the product-status boundary in CJC-1295 + GHRP-2. The WADA page addresses sport status separately.

Sources

  1. Ilson BE, et al. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69(1):212-214. PMID 2543692. https://pubmed.ncbi.nlm.nih.gov/2543692/

  2. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. PMID 2108187. https://pubmed.ncbi.nlm.nih.gov/2108187/

  3. Selman-Housein KH, et al. Clinical safety of GHRP-6 in healthy volunteers. Invest Medicoquir. 2014;6(1):81-91. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=50887

  4. Lawrence CB, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. PMID 11751604. https://pubmed.ncbi.nlm.nih.gov/11751604/

  5. PubChem. GHRP-6, CID 4345065. https://pubchem.ncbi.nlm.nih.gov/compound/4345065

  6. World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

Voix d'experts

Ce que disent les experts

Les commentaires sont des opinions et ne font pas partie de l'examen des preuves ; leur inclusion ne vaut pas approbation.

Aucun commentaire d’expert vérifié n’a été trouvé pour ce composé dans les sources acceptées par cet atlas — littérature évaluée par les pairs, communications universitaires, hospitalières et de sociétés médicales, autorités réglementaires, et journalisme scientifique signé.

L’absence de commentaire ne constitue pas une preuve pour ou contre le composé.

Les affirmations émanant de fournisseurs, cliniques et médias sociaux sont exclues par politique et ne sont pas comptées comme commentaires.

Aucune vidéo d’expert vérifiée n’a été trouvée pour ce composé dans les sources de cet atlas.

L’absence de vidéo ne constitue pas une preuve pour ou contre le composé.

Les vidéos de fournisseurs et de médias sociaux sont exclues par politique et ne sont pas comptées.

Questions

What does the marketed CJC-1295 plus GHRP-6 blend contain?

Listings pair GHRP-6 with a substance labeled CJC-1295 no DAC, usually meaning Modified GRF 1-29. That no-DAC substance is not the CJC-1295 DAC conjugate from the cited clinical research.

Has CJC-1295 plus GHRP-6 been studied as a specific combination?

No published human or animal study of the specific marketed pair was identified. Related findings come from CJC-1295 DAC and GHRP-6 studies that remain attached to their own exact materials.

What safety uncertainties apply to CJC-1295 plus GHRP-6?

No combination-specific or long-term safety evidence was identified. GHRP-6 studies measured additional pituitary-hormone responses, while the cited appetite finding was preclinical; neither establishes the safety of the marketed pair.

Were the cited GHRP-6 studies studies of this blend?

No. They studied GHRP-6 alone or with GHRH under study conditions, not the seller-labeled no-DAC substance combined with GHRP-6.

Why can't DAC data be assigned to a no-DAC product?

CJC-1295 with DAC and Modified GRF 1-29 are different molecular forms. Evidence for the albumin-binding DAC conjugate therefore cannot define the no-DAC material's effects.

What combination-quality evidence was identified for CJC-1295 plus GHRP-6?

None for co-formulation stability or compatibility. A market listing or the material's appearance cannot establish either quality attribute.